Showing 5341-5350 of 9401 results for "".
- IPC Weighs In On COVID-19 Vaccine Safety and Psoriasishttps://practicaldermatology.com/news/ipc-weighs-in-on-covid-19-vaccine-safety-and-psoriasis/2460623/The International Psoriasis Council (IPC) released guidance on the potential impact of psoriasis therapy, particularly systemic therapy, on a SARS-CoV-2 vaccine. The principal considerations for SARS-CoV-2 vaccines are the same as for any vaccine, the IPC notes. Avo
- Study: Iron Oxides Offer Protection Skin from Blue Lighthttps://practicaldermatology.com/news/study-iron-oxides-protection-skin-from-blue-light/2460616/Iron oxides provide enhanced protection against HEV or blue light, especially when combined with zinc oxide, according to results of a new study in The Journal of Cosmetic Dermatology. HEV
- Crown Aesthetics Scores Class IIa CE Certification for SkinPen Precision from British Standards Institutionhttps://practicaldermatology.com/news/crown-aesthetics-scores-class-iia-ce-certification-for-skinpen-precision/2460614/The British Standards Institution (BSI) granted a Class IIa CE Certification mark to Crown Aesthetics’ SkinPen Precision. The certification confirms SkinPen as a treatment to improve the appearance of facial acne scars in adults aged 22 years or older and to improve the appe
- AAD Names Drs. Daval Bhanusali and Cory Maughan Patient Care Heroes for Treating Young Dog Bite Victimhttps://practicaldermatology.com/news/aad-names-drs-daval-bhanusali-and-cory-maughan-patient-care-heroes-for-treating-young-dog-bite-victim/2460611/Dhaval Bhanusali, MD, FAAD, and Cory Maughan, DO, FAAD, are American Academy of Dermatology (AAD) Patient Care Heroes for providing life-changing scar treatment to a young dog bite victim. Six-year-old Bridger Walker acted quickly and courageously when a dog tried to attack hi
- AAD Names Dr. Sacharitha Bowers a Patient Care Hero for Helping Address Disparities in Care Due to COVID-19https://practicaldermatology.com/news/aad-names-dr-sacharitha-bowers-a-patient-care-hero-for-helping-address-disparities-in-care-due-to-covid-19/2460610/Sacharitha Bowers, MD, FAAD, is an American Academy of Dermatology (AAD) Patient Care Hero for her role in addressing disparities in care related to COVID-19 in Springfield, Ill. Leveraging years of relationship-building with local organizations and community members, the Southern Illin
- More Positive Phase 3 Data for Pfizer's Abrocitinib in ADhttps://practicaldermatology.com/news/more-positive-phase-3-data-for-pfizers-abrocitinib-in-ad/2460607/Positive top-line results from the phase 3 JADE REGIMEN study offer additional data in support of Pfizer's investigational oral once-daily Janus kinase 1 (JAK1) inhibitor for atopic dermatitis (AD). The 52-week study looked at patients 12 and older wi
- Bristol Myers Squibb's Deucravacitinib Performs Well in Phase 2 Study in Patients with Psoriatic Arthritishttps://practicaldermatology.com/news/bristol-myers-squibbs-deucravacitinib-performs-well-in-phase-2-study-in-patients-with-psoriatic-arthritis/2460605/Results from an ongoing Phase 2 study evaluating the safety and efficacy of Bristol Myers Squibb's deucravacitinib (BMS-986165) 6mg or 12mg once daily, compared with placebo in
- Arena’s Etrasimod Performs Well in Phase 2b AD Trialhttps://practicaldermatology.com/news/arenas-etrasimod-performs-well-in-phase-2b-ad-trial/2460604/Nearly one-third of participants in the 2 mg etrasimod group achieved clear or almost clear skin, as defined by the validated Investigator Global Assessment (vIGA), the FDA endpoint for Phase 3 registration, according to topline results from Arena’s Phase 2b ADVISE clinical trial evaluating
- Study: “Baby Botox” Boosts Skin Texture, Shrinks Poreshttps://practicaldermatology.com/news/study-baby-botox-boosts-skin-texture-shrinks-pores/2460603/Using many tiny doses of botulinum toxin injected in a grid pattern just under the surface of the facial skin may improve skin texture and roughness, according to a
- Tremfya Reduces Fatigue in PsAhttps://practicaldermatology.com/news/tremfya-reduces-fatigue-in-psa/2460602/The IL-23 blocker Tremfya (guselkumab) improves fatigue in adult patients with active psoriatic arthritis (PsA) and this response is maintained through 52 weeks of active treatment, according to data from two Phase 3 clinical trials, DISCOVER-1 and DISCOVER-2. Tremfya improved